Kiras Ventures

Kiras is a biotechnology company focused on the discovery and development of next-generation small molecule inhibitors for KRAS-mutated cancers. The company specifically targets high-prevalence mutations such as G12D, G12V, and G12R, which have historically been difficult to treat with first-generation KRAS inhibitors. Kiras leverages deep expertise in structural biology and KRAS biochemistry to design potent and selective therapies for solid tumors, including pancreatic, colorectal, and lung cancers. Founded by industry veterans and backed by leading life science investors, the company aims to expand the reach of RAS-targeted therapies to a broader patient population. Its pipeline consists of multiple pre-clinical programs designed to overcome resistance mechanisms and improve clinical outcomes in oncology.